Zydus Lifesciences launches Rexigo
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Subscribe To Our Newsletter & Stay Updated